The efficacy of drug-eluting bead or conventional transarterial chemoembolization plus apatinib for hepatocellular carcinoma with portal vein tumor thrombus

Weihua Zhang1,3, Linxia Wu1,3, Lei Chen1,3, Tao Sun1,2, Yanqiao Ren1,2, Bo Sun1,2, Licheng Zhu1,2, Ping Han1* & Chuansheng Zheng1,2*

Transarterial chemoembolization (TACE) combined with apatinib has been used for advanced hepatocellular carcinoma (HCC), and the efficacy is good. The study was conducted to compare the efficacy and safety of drug-eluting bead TACE plus apatinib (D-TACE-A) with conventional TACE plus apatinib (C-TACE-A) in the treatment of HCC with portal vein tumor thrombus (PVTT). A total of 130 continuous patients who received D-TACE-A or C-TACE-A were included in the study from January 2017 to June 2020. Propensity score matching (PSM) was used to reduce potential selection bias. Before PSM, the median overall survival (mOS) (14 months) and median progression-free survival (mPFS) (7 months) in the C-TACE-A group were longer than the mOS (9 months; P = 0.001) and mPFS (4 months; P = 0.001) in the D-TACE-A group. After PSM, the mOS (14 months vs 9 months; P = 0.039) and mPFS (7 months vs 5 months; P = 0.009) in the C-TACE-A group were longer than those in the D-TACE-A group. In the multivariate regression analysis, C-TACE-A reduced the mortality rate and tumor progression rate compared with D-TACE-A. For the subgroup analysis, patients with VP1–2, without extrahepatic metastases, and with multiple TACE sessions who received C-TACE-A had a lower death risk and tumor progression risk than patients who received D-TACE-A. Before PSM, there was no statistically significant difference in any grade or grade III/IV adverse events (all P > 0.05). C-TACE-A could prolong mOS and mPFS in patients with PVTT, especially for patients with VP1–2 stage PVTT, no extrahepatic tumor metastases, and multiple TACE sessions.

Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers worldwide. In 2020, 905,677 new HCC cases were diagnosed and 830,180 patients died from HCC worldwide1. The most commonly used classification for HCC is the Barcelona Clinic Liver Cancer (BCLC) stage2. For patients with early HCC (BCLC stage A), the European Association for the Study of the Liver (EASL) guidelines recommend radical treatments (transplantation, liver resection, or ablation) as the first-line treatments3. However, most patients are at an intermediate or advanced stage when they are diagnosed with HCC. For patients with advanced HCC, sorafenib and lenvatinib are recommended as their first-line choice (the median survival time of patients from sorafenib or Lenvatinib were 10.7 months and 13.6 months)13. However, for advanced HCC patients with portal vein tumor thrombus (PVTT), the survival of patients who receive sorafenib is not satisfactory. Thus, combination treatments are used in the treatment of HCC patients with PVTT. Previous studies have shown that transarterial chemoembolization (TACE) combined with sorafenib could prolong the survival of HCC patients with PVTT16-19. However, sorafenib is so expensive that many patients with advanced HCC cannot afford it, and the low response of sorafenib in the treatment of patients with advanced HCC has limited its usage in some advanced HCC patients. Thus, another selective drug, apatinib, is now used in the treatment of advanced HCC.

1Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 2Department of Interventional Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China. 3These authors contributed equally: Weihua Zhang, Linxia Wu and Lei Chen. *email: cjr.hanping@vip.163.com; hqczsxh@sina.com
Some studies have shown that patients with advanced HCC can obtain more survival benefits from TACE plus apatinib than TACE alone\textsuperscript{10–12}. However, two kinds of TACE (conventional TACE, C-TACE; and drug-eluting bead TACE, D-TACE) techniques are being used in the treatment of HCC. Previous high-quality studies have shown that patients with unresectable HCC who received D-TACE could obtain comparable survival benefits to those who received C-TACE, but D-TACE can reduce the pain of patients after the procedure\textsuperscript{13–16}. However, there are few studies comparing the efficacy and safety of HCC patients receiving C-TACE plus other treatments with patients receiving D-TACE plus other treatments. Whether the survival benefits of HCC patients with PVTT who received D-TACE plus apatinib (D-TACE-A) are comparable with those of patients who received C-TACE plus apatinib (C-TACE-A) is still unclear. Few studies have focused on the combination treatments of C-TACE-A or D-TACE-A for the treatment of HCC patients with PVTT.

Thus, this study was conducted to compare the efficacy and safety of HCC patients with PVTT who received C-TACE-A with patients who received D-TACE-A.

**Materials and methods**

**Patient selection.** This retrospective study reviewed data from 385 patients receiving TACE-A from January 2017 to June 2020. After inclusion criteria and exclusion criteria, a total of 130 patients were included in the study. This study was approved by the Ethics Committee Board of Tongji Medical College, Huazhong University of Science and Technology, and informed consent was waived because this is a retrospective study.

The inclusion criteria were as follows: (1) patients were diagnosed with HCC with PVTT by CT, MRI, or ultrasound based on the EASL guidelines\textsuperscript{3}; (2) patients received TACE plus apatinib; (3) patients had Child–Pugh classification A or B; (4) patients had Eastern Cooperative Oncology Group (ECOG) scores of 0, 1, or 2; and (5) patients had complete follow-up data.

The exclusion criteria were as follows: (1) patients who received sorafenib, lenvatinib, or apatinib before being included in the study; (2) Patients with Child-Pugh C; (3) patients with platelet counts less than $50 \times 10^9$/L; and (4) patients lost to follow-up (Fig. 1).

**Operation technique and drug administration.** TACE protocol. TACE protocol was performed as described in the previous study\textsuperscript{17}. After access to the femoral artery by the Seldinger technique under local anesthesia,
a 5F catheter was positioned into the celiac artery. Celiac angiography was performed to relocate the tumor. Then, a 5F catheter or 3F microcatheter was inserted into the tumor artery according to the vascular anatomy.

For C-TACE, an emulsion mixed with lipiodol (10–20 mL) and epirubicin (5–20 mg) and subsequent 500–700 μm absorbable gelatin sponge particles (Alicon Medical Co., Hangzhou, China) were injected into the tumor feeding artery for chemoembolization.

For D-TACE, CalliSphere beads (100–300 μm, Jiangsu Hengrui Medicine Co., Ltd., China) which was a special network of microsphere composed of polyvinyl alcohol backbone with hydroxyl groups and negatively charged sulfonate groups, which interact with positively charged anthracenes by means of ion exchange, hydrogen bonding, and embedding mechanisms carrying epirubicin (80 mg) were injected into the tumor feeding artery for chemoembolization.

**Apatinib administration.** Apatinib was administrated as the previous study stated. In both groups, apatinib (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) was orally administered at an initial dose of 500 mg/day 3 days after the first TACE procedure. In the following TACE procedure, apatinib was started and suspended 3 days before and after each TACE procedure. The grading of adverse events related to apatinib was conducted according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). If serious adverse events (grade ≥ 3) were observed, a reduction to half of the dose was permitted until serious adverse events were eliminated. If these serious adverse events did not disappear after the dose reduction, the administration of apatinib would be interrupted temporarily. When these serious adverse events were eliminated, apatinib was orally retaken at a dose of 250 mg/day.

**The endpoints and their definition.** The primary endpoints of the study were overall survival (OS) and progression-free survival (PFS). OS was defined as the interval between the time of initial TACE and the patient’s death or the follow-up deadline. PFS was defined as the interval between the time of initial TACE and tumor progression, patient death, or the follow-up deadline based on the mRECIST. The secondary endpoints were the objective response rate (ORR) and disease control rate (DCR). The ORR was defined as the percent of the total number of patients who had a complete response (CR) and partial response (PR) after receiving TACE-A. The DCR was defined as the percent of the total number of patients who had a complete response (CR), partial response (PR), and stable disease (SD) after receiving TACE-A based on the mRECIST.

**Follow-up.** Patients with PVTT who received TACE-A from January 2017 to June 2020 were retrospectively reviewed. The deadline for follow-up was June 2021. Patients were followed up every month after the initial TACE for three months and 2–3 months thereafter. Patients were asked to receive CT or MRI tests and laboratory tests at every follow-up. The CT or MRI images of patients at each follow-up were evaluated by two radiologists (one with 35 years of work experience and another with 28 years of work experience) and an interventional radiologist (with 16 years of work experience). When the tumor progressed (limited to the liver) during the follow-up, patients were recommended to receive another TACE to control the tumor.

**Statistical analysis.** Age, ALT, leukocytes, lymphocytes, platelets, tumor size, sex, HBV infection, cirrhosis, TACE session, portal invasion, tumor number, extrahepatic metastases, AFP level, Child–Pugh classification, and ECOG score were included in the analysis. Continuous variables were compared by Student’s t-test or Mann–Whitney U test. Categorical variables were compared by the chi-square test or Fisher’s exact test. The survival curves were plotted by Kaplan–Meier curves and were compared by the log-rank test. A Cox proportional regression model was used to predict the variables that might influence the survival of patients. For subgroup analysis, an adjusted Cox proportional regression model was used, and the adjusted variables were age, ALT, leukocytes, lymphocytes, platelets, tumor size, sex, HBV infection, cirrhosis, tumor number, AFP level, Child–Pugh classification, and ECOG score.

Propensity score matching (PSM) was used in the study to reduce potential selective bias. All variables were included in the PSM analysis. Nearest neighbor matching (1:1 ratio) with an optimal caliper of 0.1 without replacement was conducted, and 45 pairs of patients were generated. A P value less than 0.05 was considered a statistically significant difference. All statistical analyses were conducted by SPSS 24.0 (IBM Corp, Armonk, NY, USA).

**Written informed consent to participate.** Written informed consent was waived because this is a retrospective study.

**Guidelines for methods.** This study was carried out in compliance with the Helsinki Declaration.

**Consent for publication.** All authors approve it for publication.

**Results**

**Patients’ characteristics.** A total of 130 patients were included in the study. Among them, 77 patients received C-TACE-A, and 53 patients received D-TACE-A. There were 66 male patients and 11 female patients in the C-TACE-A group and 44 male patients and 9 female patients in the D-TACE-A group. In the C-TACE-A group, 33 patients had VP1–VP2 PVTT, and 44 patients had VP3–VP4 PVTT. In the D-TACE-A group, 23 patients had VP1–VP2 PVTT, and 30 patients had VP3–VP4 PVTT. The mean age in the C-TACE-A group was 51.3 years, and that in the D-TACE-A group was 53.1 years (Table 1).
Survival and tumor response before PSM. The median OS (mOS) (14 months, 95% CI 11.7–16.3 months; vs 9 months, 95% CI 8–10 months; P = 0.002) and median PFS (mPFS) (7 months, 95% CI 6.1–7.9 months; vs 4 months, 95% CI 2.9–5.1 months; P = 0.001) in the C-TACE-A group was longer than the mOS and mPFS in the D-TACE-A group (Fig. 2).

The tumor response of 41 patients was PR, 16 patients had SD, and 20 patients had PD in the C-TACE group. The tumor response of 14 patients was PR, 13 patients had SD, and 26 patients had PD in the D-TACE-A group. The ORR (53.2% vs 26.4%; P = 0.002) and DCR (74% vs 50%; P = 0.007) in the C-TACE-A group were higher than those in the D-TACE-A group (Table 2).

Predictors for OS and PFS. The univariate analysis showed that the variables ALT (HR 1.003, 95% CI 1.001–1.006; P = 0.021), leukocytes (HR 1.141, 95% CI 1.056–1.233; P = 0.001), tumor size (HR 1.066, 95% CI 1.026–1.108; P = 0.001), TACE session (HR 0.127, 95% CI 0.076–0.212; P < 0.001), portal invasion (HR 2.729, 95% CI 1.859–4.007; P < 0.001), Child–Pugh (HR 3.187, 95% CI 2.104–4.825; P < 0.001), ECOG (1 vs 0: HR 4.908, 95% CI 2.969–8.111; P < 0.001; 2 vs 0: HR 11.710, 95% CI 6.737–20.352; P < 0.001), and treatment (HR 0.568, 95% CI 0.390–0.826; P = 0.003) might influence the OS of all patients. When these variables were included in multivariate analysis, the results showed that TACE session (HR 0.297, 95% CI 0.169–0.522; P < 0.001), portal invasion (HR 1.667, 95% CI 1.055–2.634; P = 0.029), Child–Pugh (HR 1.790, 95% CI 1.097–2.922; P = 0.020), and other variables were included in multivariate analysis, the results showed that TACE session (HR 0.297, 95% CI 0.169–0.522; P < 0.001), portal invasion (HR 1.667, 95% CI 1.055–2.634; P = 0.029), Child–Pugh (HR 1.790, 95% CI 1.097–2.922; P = 0.020),

Table 1. The baseline characteristics of patients before PSM and after PSM.
ECOG (1 vs 0: HR 4.928, 95% CI 2.816–8.622; P < 0.001; 2 vs 0: HR 12.300, 95% CI 6.455–23.436; P < 0.001), and treatment (HR 0.387, 95% CI 0.253–0.591; P < 0.001) were independent predictors for OS (Table 3). For PFS, the univariate analysis showed that the variables ALT (HR 1.004, 95% CI 1.000–1.014; P = 0.027), leukocytes (HR 1.125; 95% CI 1.039–1.219; P = 0.004), tumor size (HR 1.055, 95% CI 1.016–1.095; P = 0.005), TACE session (HR 0.198, 95% CI 0.122–0.322; P < 0.001), portal invasion (HR 2.759, 95% CI 1.889–4.029; P < 0.001), Child–Pugh (HR 2.181; 95% CI 1.457–3.263; P < 0.001), ECOG (1 vs 0: HR 3.322, 95% CI 2.076–5.316; P < 0.001; 2 vs 0: HR 7.222, 95% CI 4.255–12.257; P < 0.001), and HR 0.559, 95% CI 0.389–0.804; P = 0.002) might influence tumor progression. In the multivariate analysis, TACE session (HR 0.397, 95% CI 0.229–2.869; P = 0.001), portal invasion (HR 1.855, 95% CI 1.200–2.869; P = 0.005), ECOG (1 vs 0: HR 3.083, 95% CI 1.850–5.135; P < 0.001; 2 vs 0: HR 6.976, 95% CI 3.731–113.044; P < 0.001), and treatment (HR 0.402, 95% CI 0.270–0.600; P < 0.001) were independent predictors for PFS (Table 4).

### Subgroup analysis.

The adjusted Cox proportional regression model showed that patients with VP1–VP2 (HR 0.156, 95% CI 0.063–0.389; P < 0.001), VP3–VP4 (HR 0.439, 95% CI 0.227–0.851; P = 0.015), without extrahepatic metastases (HR 0.252, 95% CI 0.116–0.545; P < 0.001), with one TACE session (HR 0.194, 95% CI 0.054–0.700; P = 0.012), and with multiple TACE sessions (HR 0.343, 95% CI 0.195–0.602; P < 0.001) who received C-TACE-A had a lower risk of death than patients who received D-TACE-A (Table 5). However, for PFS, only patients with VP1–VP2 (HR 0.155, 95% CI 0.065–0.370; P < 0.001), without extrahepatic metastases (HR 0.334, 95% CI 0.165–0.673; P = 0.002), and with multiple TACE sessions (HR 0.431, 95% CI 0.265–0.702; P = 0.001) who received C-TACE-A had a lower tumor progression risk than patients who received D-TACE-A (Table 6).

### Survival and tumor response after PSM.

The mOS (14 months, 95% CI 11.2–16.8 months) and mPFS (7 months, 95% CI 5.9–8.1 months) in the C-TACE-A group were longer than the mOS (9 months, 95% CI 6.5–11.5 months; P = 0.039) and mPFS (5 months, 95% CI 3.7–6.3 months; P = 0.009) in the D-TACE-A group (Fig. 3). The ORR (48.9%) in the C-TACE-A group was higher than the ORR (31.1%; P = 0.021) in the D-TACE-A group. However, there was no statistically significant difference in DCR (64.4% vs 57.8%; P = 0.317) between the two groups (Table 2).

---

**Table 2.** Analysis for tumor response at 3 months after patients receiving TACE-A.

| Tumor response       | Before matching | After matching | P value | Before matching | After matching | P value |
|----------------------|-----------------|----------------|---------|-----------------|----------------|---------|
|                      | C-TACE-A        | D-TACE-A       |         | C-TACE-A        | D-TACE-A       |         |
| Partial response     | 41              | 14             | –       | 23              | 13             | –       |
| Stable disease       | 16              | 13             | –       | 6               | 12             | –       |
| Progressive disease  | 20              | 26             | –       | 15              | 20             | –       |
| Objective response   | 53.2%           | 26.4%          | 0.002   | 48.9%           | 31.1%          | 0.021   |
| Disease control rate | 74%             | 50%            | 0.007   | 64.4%           | 57.8%          | 0.317   |

**Figure 2.** Kaplan–Meier curves of overall survival and progression-free survival in the patients before PSM. (A) Kaplan–Meier curve for overall survival; (B) Kaplan–Meier curve for progression-free survival.
Safety. The adverse events of patients with TACE-A were reported and evaluated. For all grades of adverse events, there was no statistically significant difference in fever, fatigue, nausea, vomiting, diarrhea, hand-foot syndrome, hypertension, proteinuria, or hyperbilirubinemia between the C-TACE-A group and D-TACE-A group (all P > 0.05). However, the adverse event of pain was significantly higher in the C-TACE-A group than that in the D-TACE-A group (34 patients vs 9 patients; P = 0.001). For serious adverse events (grades III and IV), there was no statistically significant difference in any adverse events reported in the study (all P > 0.05) (Table 7).

Discussion
HCC patients with PVTT have a dismal prognosis. Recently, some studies have shown that HCC patients could obtain more survival benefits from C-TACE plus apatinib than TACE alone. However, the efficacy and safety of HCC patients with PVTT who received D-TACE-A have not been reported. Thus, the study was conducted to compare the efficacy and safety of C-TACE-A and D-TACE-A in the treatment of HCC patients with PVTT.

| Characteristics         | Univariate analysis | Multivariate analysis |
|-------------------------|---------------------|-----------------------|
|                         | HR (95% CI)        | P value   | HR (95% CI)        | P value   |
| Age (years)             | 1.003 (0.986, 1.020) | 0.733      |                     |           |
| ALT (U/L)               | 1.003 (1.001, 1.006) | 0.021      | 0.998 (0.994, 1.001) | 0.230      |
| Leukocyte (10^9/L)      | 1.141 (1.056, 1.233) | 0.001      | 1.073 (0.989, 1.165) | 0.090      |
| Lymphocytes (10^9/L)    | 0.741 (0.515, 1.066) | 0.106      |                     |           |
| Platelet (10^9/L)       | 1.002 (1.000, 1.004) | 0.118      |                     |           |
| Tumor size (cm)         | 1.066 (1.026, 1.108) | 0.001      | 1.918 (0.976, 1.062) | 0.415      |
| Gender                  |                     | 0.089      |                     |           |
|                         | Male                | 1          |                     |           |
|                         | Female              | 0.632 (0.372, 1.073) | 0.907      |           |
|                         | Yes                 | 1          |                     |           |
|                         | No                  | 1.030 (0.629, 1.685) | 0.522      |           |
| HBV infection           |                     | 0.907      |                     |           |
|                         | Yes                 | 1          |                     |           |
|                         | No                  | 1.135 (0.770, 1.672) | < 0.001    | < 0.001   |
| TACE session            |                     |            |                     |           |
|                         | Once                | 1          | 1                    |           |
|                         | Multiple            | 0.127 (0.076, 0.212) | 0.297 (0.169, 0.522) | 0.029      |
| Portal invasion         |                     | < 0.001    |                     |           |
|                         | VP1–VP2             | 1          | 1                    |           |
|                         | VP3–VP4             | 2.729 (1.859, 4.007) | 1.667 (1.055, 2.634) |           |
| Tumor number            |                     | 0.688      |                     |           |
|                         | 1                   | 1          |                     |           |
|                         | ≥ 2                 | 1.077 (0.750, 1.548) |           |           |
| Extrahepatic metastases |                     | 0.100      |                     |           |
|                         | Yes                 | 1          |                     |           |
|                         | No                  | 0.736 (0.510, 1.061) |           |           |
| AFP level               |                     | 0.083      |                     |           |
|                         | < 200 (ug/L)        | 1          |                     |           |
|                         | ≥ 200 (ug/L)        | 1.410 (0.957, 2.077) |           |           |
| Child–Pugh              |                     | < 0.001    |                     | 0.020     |
|                         | A                   | 1          |                     |           |
|                         | B                   | 3.187 (2.104, 4.825) | 1.790 (1.097, 2.922) |           |
| ECOG                    |                     |            |                     |           |
|                         | 0                   | 1          |                     |           |
|                         | 1                   | 4.908 (2.969, 8.111) | < 0.001    | 4.928 (2.816, 8.622) | < 0.001   |
|                         | 2                   | 11.710 (6.737, 20.352) | < 0.001   | 12.300 (6.455, 23.436) | < 0.001   |
| Treatment               |                     | 0.003      |                     | < 0.001   |
|                         | D-TACE-A            | 1          |                     |           |
|                         | C-TACE-A            | 0.568 (0.390, 0.826) | 0.387 (0.253, 0.591) |           |

Table 3. Univariate regression analysis and multivariate regression analysis for OS before PSM.
The main findings of the study were that HCC patients with PVTT could obtain more survival benefits from C-TACE-A than D-TACE-A, especially patients with VP1–VP2, without extrahepatic metastases, and with multiple TACE sessions. The ORR at three months after the initial TACE of the C-TACE-A group was higher than that of the D-TACE-A group. The reason for the results might be that the embolic agent of lipiodol has strong fluidity, which can flow into the tumor thrombus and stay in the tumor thrombus, achieving a good embolization effect. A previous study showed that the mOS of HCC patients receiving C-TACE-A was 12 months, which was less than the mOS from the current study. The DCR (59%) in that study was also lower than the DCR (74%) in the current study. The reason might be that they included more patients with high stage PVTT than the patients included in the current study because the PVTT stage could influence the survival of patients by multivariate analysis. Another study included 19 HCC patients with PVTT who received D-TACE-A. The results showed that the mOS, mPFS, ORR, and DCR at 1 month after the initial TACE of the 19 patients were 11.9 months, 8.1 months, 63.15%, and 84.21%, respectively, which were all higher than the mOS, ORR, and DCR in the current study. The ORR and DCR of that study were higher than those in the current study, possibly because they evaluated the 1st-month tumor response after the initial TACE, but the current study evaluated the 3rd-month.

### Table 4. Univariate regression analysis and multivariate regression analysis for PFS before PSM.

| Characteristics          | Univariate analysis | Multivariate analysis |
|--------------------------|---------------------|-----------------------|
|                          | HR (95% CI)         | P value               |
|                          | HR (95% CI)         | P value               |
| Age (years)              | 0.998 (0.983, 1.014)| 0.834                 |
| ALT (U/L)                | 1.004 (1.000, 1.007)| 0.027                 |
| Leukocyte (10^9/L)       | 1.125 (1.039, 1.219)| 0.004                 |
| Lymphocytes (10^9/L)     | 0.742 (0.528, 1.043)| 0.086                 |
| Platelet (10^9/L)        | 1.001 (0.999, 1.003)| 0.201                 |
| Tumor size (cm)          | 1.055 (1.016, 1.095)| 0.005                 |
| Gender                   |                     | 0.187                 |
| Male                     | 1                   |                       |
| Female                   | 0.717 (0.437, 1.176)|                       |
| HBV infection            |                     | 0.418                 |
| Yes                      | 1                   |                       |
| No                       | 0.819 (0.504, 1.329)|                       |
| Cirrhosis                |                     | 0.429                 |
| Yes                      | 1                   |                       |
| No                       | 1.160 (0.803, 1.675)|                       |
| TACE session             | < 0.001             | 0.001                 |
| Once                     | 1                   | 1                     |
| Multiple                 | 0.198 (0.122, 0.322)| 0.397 (0.229, 2.869)  |
| Portal invasion          | < 0.001             | 0.005                 |
| VP1–VP2                  | 1                   | 1                     |
| VP3–VP4                  | 2.759 (1.889, 4.029)| 1.855 (1.200, 2.869)  |
| Tumor number             | 0.636               |                       |
| ≥ 2                      | 0.919 (0.646, 1.306)|                       |
| Extrahepatic metastases  |                     | 0.084                 |
| Yes                      | 1                   |                       |
| No                       | 0.733 (0.514, 1.043)|                       |
| AFP level                | 0.074               |                       |
| < 200 (ug/L)             | 1                   |                       |
| ≥ 200 (ug/L)             | 1.403 (0.968, 2.034)|                       |
| Child–Pugh               | < 0.001             | 0.747                 |
| A                        | 1                   | 1                     |
| B                        | 2.181 (1.457, 3.263)| 1.081 (0.672, 1.740)  |
| ECOG                     |                     |                       |
| 0                        | 1                   | 1                     |
| 1                        | 3.322 (2.076, 5.316)| < 0.001               |
| 2                        | 7.222 (4.235, 12.257)| < 0.001               |
| Treatment                |                     | 0.002                 |
| D-TACE-A                 | 1                   | 1                     |
| C-TACE-A                 | 0.559 (0.389, 0.804)| 0.402 (0.270, 0.600)  | < 0.001
### Table 5. Adjusted Cox proportional risk analysis of OS for subgroup analysis before PSM. Adjusted for age, ALT, leukocyte, lymphocytes, platelet, tumor size, gender, HBV infection, cirrhosis, TACE session, tumor number, AFP level, Child–Pugh, ECOG.

| Characteristics          | Crude analysis | Adjusted analysis |
|--------------------------|----------------|-------------------|
|                          | HR (95% CI)    | P value           | HR (95% CI)    | P value           |
| Portal invasion          |                |                   |                |                   |
| VP1–VP2                  | 0.026          | < 0.001           |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.513 (0.285, 0.923) | 0.156 (0.063, 0.389) |                   |                   |
| VP3–VP4                  | 0.011          | 0.015             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.525 (0.319, 0.864) | 0.439 (0.227, 0.851) |                   |                   |
| Extrahepatic metastases  |                |                   |                |                   |
| With extrahepatic metastases | 0.191         | 0.086             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.709 (0.423, 1.187) | 0.572 (0.303, 1.045) |                |                   |
| Without extrahepatic metastases | 0.004         | < 0.001           |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.440 (0.253, 0.765) | 0.252 (0.116, 0.545) |                |                   |
| TACE session             |                | 0.012             |                |                   |
| Once                     | 0.244          |                   |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.624 (0.2882, 1.380) | 0.194 (0.054, 0.700) |                |                   |
| Multiple                 | 0.012          | < 0.001           |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.573 (0.372, 0.883) | 0.343 (0.195, 0.602) |                |                   |

### Table 6. Adjusted Cox proportional risk analysis of PFS for subgroup analysis before PSM. Adjusted for age, ALT, leukocyte, lymphocytes, platelet, tumor size, gender, HBV infection, cirrhosis, tumor number, AFP level, Child–Pugh, ECOG.

| Characteristics          | Crude analysis | Adjusted analysis |
|--------------------------|----------------|-------------------|
|                          | HR (95% CI)    | P value           | HR (95% CI)    | P value           |
| Portal invasion          |                |                   |                |                   |
| VP1–VP2                  | 0.003          | < 0.001           |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.424 (0.242, 0.744) | 0.155 (0.065, 0.370) |                |                   |
| VP3–VP4                  | 0.074          | 0.278             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.649 (0.405, 1.042) | 0.722 (0.401, 1.300) |                |                   |
| Extrahepatic metastases  |                |                   |                |                   |
| With extrahepatic metastases | 0.115         | 0.077             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.672 (0.410, 1.102) | 0.585 (0.323, 1.060) |                |                   |
| Without extrahepatic metastases | 0.009         | 0.002             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.490 (0.287, 0.838) | 0.334 (0.165, 0.673) |                |                   |
| TACE session             |                |                   |                |                   |
| Once                     | 0.287          | 0.266             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.640 (0.282, 1.454) | 0.504 (0.151, 1.686) |                |                   |
| Multiple                 | 0.006          | 0.001             |                |                   |
| D-TACE-A                 | 1              |                   | 1              |                   |
| C-TACE-A                 | 0.559 (0.370, 0.846) | 0.431 (0.265, 0.702) |                |                   |
tumor response after the initial TACE. The samples of previous studies and the current study were not larger, which might lead to the heterogeneity of patients being large and the different survival results of different studies. Thus, a larger sample study is needed to confirm the results of the current study.

Multivariate Cox regression analysis is common used to exclude the influence of potential factors on the results. In the study, we conducted the univariate regression analysis and the factors with P value less than 0.05 in the univariate regression analysis were included into multivariate regression analysis to reduce the rate of collinearity. The multivariate regression analysis in the study showed that patients with C-TACE-A had a lower all-cause mortality risk and tumor progression risk than patients with D-TACE-A, which showed that HCC patients with PVTT could still obtain more survival benefits from C-TACE-A than D-TACE-A after excluding potential influencing factors.

The results of previous studies and the current study showed that TACE sessions, PVTT stage, and extrahepatic metastases could influence the survival of patients. Thus, subgroup analysis was conducted based on the factors. After adjusting for relative variables, the results showed that patients with VP1–VP2 PVTT, without extrahepatic metastases, and with multiple TACE sessions could obtain more survival benefits from C-TACE-A than D-TACE-A. The results might be used for clinics to select more suitable treatments for these patients.

This study reported all-grade adverse events and serious adverse events of patients with C-TACE-A and D-TACE-A. The results showed that patients in the C-TACE-A group had a higher pain risk than patients in the D-TACE-A group. The result was consistent with previous studies. For serious adverse events, there was no statistically significant difference in adverse events between the two groups, which should be because C-TACE-A was as safe as D-TACE-A in the treatment of HCC patients with PVTT because grade I and II adverse events could be cured well by symptomatic treatment.

There are some limitations existing in the study. First, although PSM was conducted in the study, selection bias was inevitable because the study was retrospective. Second, the sample of the study was not large, which

---

**Table 7.** The adverse events of patients with TACE-A before PSM.

| Adverse events               | All grades | III and IV grades |
|------------------------------|------------|------------------|
|                              | C-TACE-A (N/%) | D-TACE-A (N/%) | P value | C-TACE-A (N/%) | D-TACE-A (N/%) | P value |
| Fever                        | 39 (50.6)  | 32 (60.4)        | 0.087   | 5 (6.5)      | 5 (9.4)        | 0.777   |
| Fatigue                      | 24 (31.2)  | 16 (30.2)        | 0.905   | 2 (2.6)      | 1 (1.9)        | 0.789   |
| Pain                         | 34 (44.2)  | 9 (17.0)         | 0.001   | 8 (10.4)     | 2 (3.8)        | 0.198   |
| Nausea                       | 21 (27.3)  | 16 (30.2)        | 0.408   | 3 (3.9)      | 1 (1.9)        | 0.892   |
| Vomiting                     | 15 (19.5)  | 12 (22.6)        | 0.662   | 1 (2.3)      | 2 (3.8)        | 0.567   |
| Diarrhea                     | 11 (14.3)  | 12 (22.6)        | 0.220   | 0 (0)        | 1 (1.9)        | 0.468   |
| Hand-foot syndrome           | 16 (20.8)  | 14 (26.4)        | 0.454   | 3 (3.9)      | 3 (5.6)        | 0.687   |
| Hypertension                 | 25 (32.5)  | 20 (37.3)        | 0.535   | 5 (6.5)      | 4 (7.5)        | 0.817   |
| Proteinuria                  | 12 (15.6)  | 11 (20.8)        | 0.448   | 1 (2.3)      | 0 (0)          | > 0.999 |
| Hyperbilirubinemia           | 5 (6.5)    | 5 (9.4)          | 0.777   | 0 (0)        | 0 (0)          | > 0.999 |

---

**Figure 3.** Kaplan–Meier curves of overall survival and progression-free survival in the patients after PSM. (A) Kaplan–Meier curve for overall survival; (B) Kaplan–Meier curve for progression-free survival.
might influence the evidence strength of the results. Thus, a larger sample study or prospective research is needed to confirm this hypothesis.

**Conclusion**

This study showed that hepatocellular carcinoma patients with portal vein tumor thrombus could obtain more survival benefits from conventional transarterial chemoembolization plus apatinib than drug-eluting bead transarterial chemoembolization plus apatinib, especially for patients with VP1–VP2 PVT, without extrahepatic metastases, with multiple TACE session treatments. The results of the study might provide new evidence for clinicians to select suitable treatments for advanced hepatocellular carcinoma patients with portal vein tumor thrombus.

**Data availability**

The data can be available from the correspondence authors upon reasonable request.

Received: 13 October 2021; Accepted: 10 March 2022
Published online: 06 April 2022

**References**

1. Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J. Clin.* **71**, 209 (2021).
2. Forner, A., Reig, M. E., de Lope, C. R. & Bruix, J. Current strategy for staging and treatment: The BCLC update and future prospects. *Semin. Liver Dis.* **30**, 61–74 (2010).
3. Galle, P. R. et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J. Hepatol.* **69**, 182–236 (2018).
4. Palmer, D. H. Sorafenib in advanced hepatocellular carcinoma. *N. Engl. J. Med.* **359**, 2498 (2008).
5. Kudo, M. et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. *Lancet* **391**, 1163–1173 (2018).
6. Zhang, Y. et al. The PPPD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. *Eur. Radiol.* **31**, 232–243 (2021).
7. Yuan, J. et al. Transarterial chemoembolization (TACE) combined with sorafenib in treatment of HBV background hepatocellular carcinoma with portal vein tumor thrombus: A propensity score matching study. *Biomed. Res. Int.* **2019**, 2141859 (2019).
8. Takano, M. et al. Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma. *World J. Gastroenterol.* **22**, 9445–9450 (2016).
9. Zhu, K. et al. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib—A retrospective controlled study. *Radiology* **272**, 284–293 (2014).
10. Shen, L. et al. Transarterial chemoembolization combined with apatinib versus transarterial chemoembolization alone for hepatocellular carcinoma with macroscopic vascular invasion: A propensity score matching analysis. *J. Cancer Res. Ther.* **16**, 1063–1068 (2020).
11. Kan, X. et al. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: A propensity score matching analysis. *Front. Oncol.* **10**, 970 (2020).
12. Zhao, S. et al. A comparison of transcatheter arterial chemoembolization used with and without apatinib for intermediate- to advanced-stage hepatocellular carcinoma: A systematic review and meta-analysis. *Ann. Transl. Med.* **8**, 542 (2020).
13. Duan, F. et al. Superselective chemoembolization of HCC: Comparison of short-term safety and efficacy between drug-eluting LC beads, quadrashperes, and conventional ethiodized oil emulsion. *Radiology* **278**, 612–621 (2016).
14. Forner, A., Gilabert, M., Bruix, J. & Raoul, J. L. Treatment of intermediate-stage hepatocellular carcinoma. *Nat. Rev. Clin. Oncol.* **11**, 525–535 (2014).
15. Song, M. J. et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. *J. Hepatol.* **57**, 1244–1250 (2012).
16. Gao, S. et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: A meta-analysis. *Hepatogastroenterology*. **60**, 813–820 (2013).
17. Cao, F., Zheng, J., Luo, J., Zhang, Z. & Shao, G. Treatment efficacy and safety of regorafenib plus drug-eluting beads-transarterial chemoembolization versus regorafenib monotherapy in colorectal cancer liver metastasis patients who fail standard treatment regimens. *J. Cancer Res. Clin. Oncol.* **147**, 2993–3002 (2021).
18. Lencioni, R. & Llovet, J. M. Revised RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin. Liver Dis.* **30**, 52–60 (2010).
19. Fan, W. et al. Apatinib combined with transarterial chemoembolization in patients with hepatocellular carcinoma and portal vein tumor thrombus: A multicenter retrospective study. *Clin. Ther.* **41**, 1463–1476 (2019).
20. Liu, C., Xing, W., Si, T., Yu, H. & Guo, Z. Efficacy and safety of apatinib combined with transarterial chemoembolization for hepatocellular carcinoma with portal venous tumor thrombus: A retrospective study. *Oncotarget* **8**, 100734–100745 (2017).
21. Chen, S. et al. Lack of response to transarterial chemoembolization for intermediate-stage hepatocellular carcinoma: Abandon or repeat? *Radiology* **298**, 680–692 (2021).
22. Ni, Y. et al. A nomogram to predict survival of patients with intermediate-stage hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. *Eur. Radiol.* **30**, 2377–2390 (2020).
23. Xiang, X. et al. Transarterial chemoembolization versus best supportive care for patients with hepatocellular carcinoma with portal vein tumor thrombus: A multicenter study. *Eur. J. Surg. Oncol.* **45**, 1460–1467 (2019).
24. Zhang, X. et al. An Eastern Hepatobiliary Surgery Hospital/portal vein tumor thrombus scoring system as an aid to decision making on hepatectomy for hepatocellular carcinoma patients with portal vein tumor thrombus: A multicenter study. *Hepatology* **69**, 2076–2090 (2019).
25. Yang, J. et al. A nomogram for preoperative estimation of microvascular invasion risk in hepatocellular carcinoma: Single-Center analyses with internal validation. *Front. Oncol.* **11**, 616976 (2021).
26. Ha, Y. et al. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. *Hepatol. Int.* **14**, 776–787 (2020).
27. Goliferti, R. et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. *Br. J. Cancer* **111**, 255–264 (2014).
Author contributions
C.Z. and P.H. concepted and designed the work. W.Z. and L.W. wrote the main manuscript text. The collection and assembly of data was by L.C., Y.R., T.S. and B.S. Data analysis and interpretation was done by W.Z., L.C., and L.Z. All authors reviewed the manuscript.

Funding
This study was supported by National Natural Science Foundation of China (No. 81873919).

Competing interests
The authors declare no competing interests.

Additional information
Correspondence and requests for materials should be addressed to P.H. or C.Z.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022